NCT07340424
Recruiting
Early Phase 1
A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
Xiaorong Sun1 site in 1 country15 target enrollmentStarted: May 22, 2025Last updated:
Interventions225Ac-TR2205 Injection
Overview
- Phase
- Early Phase 1
- Status
- Recruiting
- Sponsor
- Xiaorong Sun
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- The incidence and severity grades of adverse events (AE), serious adverse events (SAE), and unexpected serious adverse reactions (SUSAR) were evaluated according to the CTCAE 5.0 standard.
Overview
Brief Summary
This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and initial efficacy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Voluntary participation in the study and signing of the informed consent form.
- •Female patients aged 18 years and above.
- •Patients with triple-negative breast cancer who have been diagnosed by histopathology \[immune histochemistry estrogen receptor (ER) positive rate \< 1% is defined as ER negative expression; progesterone receptor (PR) positive rate \< 1% is defined as PR negative; human epidermal growth factor receptor 2 (HER2) expression 0-1+ or HER2 ++ but fluorescence in situ hybridization/colorimetric in situ hybridization (FISH/CISH) negative is defined as HER2 negative expression\].
- •Patients with metastatic triple-negative breast cancer who have received at least 2 systemic treatments (at least 1 of which is for metastatic disease).
- •Patients with at least 1 measurable lesion (tumor evaluation according to RECIST 1.1).
- •ECOG performance status assessment of 0-
- •Clinical significance of hematological toxicity related to previous treatment must recover to ≤ 2 grade, and non-hematological toxicity ≤ 1 grade (except for hair loss).
- •For patients with reproductive potential: 7 days before the first administration, fertile women must confirm that the urine pregnancy test is negative and agree to use effective contraceptive measures during the use of the study drug and within 6 months after the last administration (such as oral contraceptives, intrauterine devices, restraint of sexual desire or barrier contraception combined with spermicides, etc.).
Exclusion Criteria
- •Patients who received radiotherapy (except palliative radiotherapy) or chemotherapy, immunotherapy within 3 weeks before treatment, except for bisphosphonates (which can be used for bone metastasis), are excluded.
- •Patients who received radionuclide therapy within 6 months before enrollment, such as strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, lutetium-177, actinium-225, or whole-body radiotherapy.
- •Patients who are undergoing chemotherapy, immunotherapy, biological therapy, off-label radionuclide therapy, or other investigational treatments.
- •Patients who have undergone major surgery within 28 days before enrollment.
- •Patients evaluated by the investigator are expected to have a life expectancy of less than 3 months.
- •Bone scans show super bone imaging, defined as uniform and significant concentration of radioactive isotopes in the entire skeleton relative to soft tissue, while the urinary system is not visible or shows mild visibility.
- •Symptomatic spinal cord compression, or clinical or imaging evidence suggesting impending spinal cord compression.
- •Patients with uncontrollable central nervous system (CNS) metastases, who need symptomatic treatment with glucocorticoids or mannitol, and if necessary, enhanced CT or MRI to clarify the status of brain metastases.
- •Patients with a history of other malignant tumors, except for those with fully treated malignant tumors that have survived without treatment for more than 3 years without recurrence or progression, or patients with fully treated non-melanoma skin cancer and superficial bladder cancer.
- •Patients with a history that may interfere with the purpose of the study and assessment, or the investigator determines that the patient has any condition that cannot cooperate with imaging examinations, treatment, and procedures.
Arms & Interventions
225Ac-TR2205 Injection
Experimental
Intervention: 225Ac-TR2205 Injection (Drug)
Outcomes
Primary Outcomes
The incidence and severity grades of adverse events (AE), serious adverse events (SAE), and unexpected serious adverse reactions (SUSAR) were evaluated according to the CTCAE 5.0 standard.
Time Frame: 8 weeks after the last dose
Secondary Outcomes
No secondary outcomes reported
Investigators
Xiaorong Sun
Director of Nuclear Medicine Department
Shandong Cancer Hospital and Institute
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNCT07339527Sun Yat-sen University60
Recruiting
Early Phase 1
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesNCT07275736Juventas Cell Therapy Ltd.18
Not yet recruiting
Not Applicable
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesNCT07265206Juventas Cell Therapy Ltd.15
Not yet recruiting
Not Applicable
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsNCT07279428Sichuan Baili Pharmaceutical Co., Ltd.33
Recruiting
Early Phase 1
JY232(JY232) Injection in Relapsed/Refractory Multiple MyelomaNCT07336823Shenzhen Genocury Biotech Co., Ltd.9